TFF Pharmaceuticals (Nasdaq:TFFP) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

TFFP 주식 개요

임상 단계의 바이오 제약 회사인 TFF 제약은 미국과 호주에서 특허받은 박막 동결(TFF) 기술 플랫폼을 기반으로 의약품을 개발하고 상용화하는 데 주력하고 있습니다.

TFFP 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 72.19% 증가할 것으로 예상됩니다.

위험 분석

의미 있는 시가총액이 없습니다. ( $6M )

지난 1년 동안 주주가 크게 희석되었습니다.

수익이 1백만 달러 미만인 경우 ( $886K )

최근 3개월간 주가 변동폭 심해

+ 1 더 많은 위험

TFF Pharmaceuticals, Inc. 경쟁사

Akanda

NasdaqCM:AKAN

US$4.5m

Evoke Pharma

NasdaqCM:EVOK

US$4.6m

Juva Life

OTCPK:JUVA.F

US$2.3m

Endexx

OTCPK:EDXC

US$8.1m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 TFF Pharmaceuticals
과거 주가
현재 주가	US$1.57
52주 최고치	US$13.50
52주 최저치	US$1.54
베타	1.38
11개월 변경	-28.96%
3개월 변경 사항	-74.01%
1년 변경 사항	-86.04%
33년 변화	-99.38%
5년 변화	n/a
IPO 이후 변화	-98.76%

최근 뉴스 및 업데이트

Recent updates

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

Apr 10

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

Sep 27

We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully

May 17

Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation

Jan 06

TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But Timidly

Dec 02

Companies Like TFF Pharmaceuticals (NASDAQ:TFFP) Are In A Position To Invest In Growth

Sep 16

TFF Pharmaceuticals: Cautiously Optimistic

Sep 09

TFF Pharma's Platform Is Highly Relevant In The Battle Against The Pandemic

Jul 27

주주 수익률

	TFFP	US Pharmaceuticals	US 마켓
7D	-21.1%	1.0%	0.3%
1Y	-86.0%	19.1%	22.5%

수익률 대 산업: TFFP 지난 1년 동안 17.4 %를 반환한 US Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: TFFP 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is TFFP's price volatile compared to industry and market?
TFFP volatility
TFFP Average Weekly Movement	15.5%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.8%

안정적인 주가: TFFP 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: TFFP 의 주간 변동성( 15% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2018	19	Harlan Weisman	tffpharma.com

임상 단계의 바이오 제약 회사인 TFF 제약은 미국과 호주에서 특허받은 박막 동결(TFF) 기술 플랫폼을 기반으로 의약품을 개발하고 상용화하는 데 주력하고 있습니다. 폐 질환 및 질환 치료를 위한 흡입용 건조 분말 의약품 개발에 주력할 계획입니다. 이 회사의 약물 후보로는 침습성 폐 아스페르길루스증 치료 및 예방을 위한 임상 2상 시험 중인 TFF 보리코나졸 흡입 분말과 폐 이식 거부 반응을 예방하기 위한 임상 2상 시험 중인 TFF 타크로리무스 흡입 분말이 있습니다.

TFF Pharmaceuticals, Inc. 기본 사항 요약

TFF Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
TFFP 기본 통계
시가총액	US$5.36m
수익(TTM)	-US$19.93m
수익(TTM)	US$885.72k

5.5x

P/S 비율

-0.2x

P/E 비율

TFFP 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
TFFP 손익 계산서(TTM)
수익	US$885.72k
수익 비용	US$11.50m
총 이익	-US$10.62m
기타 비용	US$9.31m
수익	-US$19.93m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-6.43
총 마진	-1,198.52%
순이익 마진	-2,249.82%
부채/자본 비율	0%

TFFP 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

TFFP 주식 개요

보상

위험 분석

TFF Pharmaceuticals, Inc. 경쟁사

NasdaqCM:AKAN

US$4.5m

NasdaqCM:EVOK

US$4.6m

OTCPK:JUVA.F

US$2.3m

OTCPK:EDXC

US$8.1m

가격 내역 및 성능

최근 뉴스 및 업데이트

Tff Pharmaceuticals, Inc. Provides Regulatory Update on Tacrolimus Inhalation Powder (Tff Tac) Clinical Program for the Prevention of Lung Transplant Rejection

Consensus revenue estimates decrease by 29%, EPS upgraded

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.055 million.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Tff Pharmaceuticals, Inc. Provides Update on Tacrolimus Inhalation Powder (Tff Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

Recent updates

Tff Pharmaceuticals, Inc. Provides Regulatory Update on Tacrolimus Inhalation Powder (Tff Tac) Clinical Program for the Prevention of Lung Transplant Rejection

Consensus revenue estimates decrease by 29%, EPS upgraded

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.055 million.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Tff Pharmaceuticals, Inc. Provides Update on Tacrolimus Inhalation Powder (Tff Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787505 million.

TFF Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024

TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions

New major risk - Market cap size

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 39%

No longer forecast to breakeven

TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.18 million.

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.18 million.

TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs

New major risk - Share price stability

TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference

Forecast to breakeven in 2026

New minor risk - Profitability

TFF Pharmaceuticals, Inc. Appoints Thomas B. King to Board of Directors

TFF Pharmaceuticals, Inc. Appoints Catherine Lee to its Board of Directors

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $35 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 40%

TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 21, 2023

Aaron Fletcher Advises TFF Pharmaceuticals, Inc. of His Decision Not to Stand for Reelection to the Board

Consensus revenue estimates increase by 37%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 21%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

No longer forecast to breakeven

No longer forecast to breakeven

Key Executive recently bought US$132k worth of stock

Consensus revenue estimates increase by 16%

TFF Pharmaceuticals, Inc. Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer

TFF Pharmaceuticals, Inc. Appoints Zamaneh Mikhak as Chief Medical Officer

Forecast to breakeven in 2025

Key Executive recently bought US$53k worth of stock

TFF Pharmaceuticals Announces Leadership Transition

Consensus revenue estimates increase by 98%

Third quarter 2022 earnings released: US$0.29 loss per share (vs US$0.34 loss in 3Q 2021)

High number of new and inexperienced directors

Price target decreased to US$16.00

TFF Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

TFF Pharmaceuticals, Inc. Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting

Independent Director exercised options and sold US$72k worth of stock

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting

TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 07, 2022

TFF Pharmaceuticals, Inc. Announces Presentation of Patient Data with Voriconazole Inhalation Powder At the 15Th International Congress on Lung Transplantation

TFF Pharma: The Potential Is Still Very Much Present

Consensus revenue estimates fall by 84%